Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 1.50% on September 22, with a trading volume of 1.263 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of September 19, 2024, the fund's latest share count was 8.17 billion shares, with a total size of 7.676 billion yuan, reflecting a year-to-date increase of 1966.38% in shares and 1931.78% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 87.92% during the management period [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The cumulative trading amount over the last 20 trading days reached 37.235 billion yuan, with an average daily trading amount of 1.862 billion yuan [1][2]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Fund Performance - As of September 18, 2024, the fund's share volume reached 8.17 billion shares, with a total size of 7.839 billion yuan, reflecting an increase of 1966.38% in share volume and 1974.81% in size compared to its initial figures on December 31, 2023 [1]. - The fund manager, Ma Jun, has achieved a return of 90.14% since taking over management on January 3, 2024 [2]. Trading Activity - The ETF recorded a trading volume of 12.58 billion yuan on September 19, 2024, with an average daily trading amount of 18.71 billion yuan over the last 20 trading days [1]. - Year-to-date, the ETF has accumulated a total trading amount of 206.404 billion yuan over 176 trading days, averaging 11.73 billion yuan per day [1]. Top Holdings - The ETF's major holdings include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].

Core Insights - The Hong Kong stock market indices experienced a collective decline, with the Hang Seng Index falling by 1.35%, the Hang Seng China Enterprises Index down by 1.46%, and the Hang Seng Tech Index decreasing by 0.99% [2] - The report highlights a significant interest in the collaboration between Nvidia and Intel, which is expected to impact the semiconductor sector positively [6] Company Overview - Chery Automobile is a leading passenger car manufacturer in China, established in 1997, with five major brands catering to diverse customer needs [8] - The company is projected to achieve revenues of 926.2 billion, 1,632.1 billion, and 2,699.0 billion CNY from 2022 to 2024, with a compound annual growth rate (CAGR) of 70.7% [8] Industry Status and Outlook - The global passenger car industry is entering a mature phase, with total sales expected to reach 74.3 million units in 2024 and a CAGR of 3.5% from 2025 to 2030 [9] - The Chinese passenger car market is robust, with sales projected to reach 22.7 million units in 2024, growing at a CAGR of 1.9% from 2019 to 2024 [9] Advantages and Opportunities - Chery Automobile boasts a diverse brand matrix and strong R&D capabilities, positioning it well for future technological advancements [10] - The company is recognized as a leading Chinese passenger car enterprise with significant global expansion potential [10] Investment Recommendations - The IPO of Chery Automobile is supported by a strong lineup of cornerstone investors, with the offering price set between 27.75 and 30.75 HKD, leading to a post-IPO market capitalization of approximately 160.04 to 177.34 billion HKD [12] - The report suggests that Chery is comparable to other leading domestic brands like Great Wall Motors and Geely, with a lower valuation relative to Geely [12]

来源：市场资讯 （来源：ETF万亿指数） 美联储降息终于落地了降。 25bp符合预期，点阵图显示年内还要降两次，有点鸽派；但是鲍威尔的表态又"不够鸽派"，so，有点纠 结。 所以，涨跌都有理，有句话说的好，符合预期就是利好兑现，跌。 对了，还有Good Afternoon的梗... 如果鲍威尔说"Good Afternoon"，就是偏鹰派，不降息或者降息没超预期，跌。 如果他说"Hello Everyone"，那就是鸽，要降息，涨！ 华尔街机构也早早的部署好了AI系统，第一时间捕捉到他舌头的微小变化，来决定买卖了... 有点失望的是，鲍威尔这回的开场是"Good Afternoon"。 自这之后，美股先涨后跌，大A似乎也复制了同样的走势，不得不服啊这预判。 那，今天聊聊降息下，大家比较关注的创新药板块，调整后还没有没有机会。 一、创新药，三重压力下暂时回调 港股通创新药ETF（520880）在连续9个交易日调整后，场内却延续高频溢价，买盘资金依然强势，这 辆创新药高速列车是否在等待更多人上车？ 港股通创新药ETF基金经理丰晨成解读，近期调整主要源于三重因素叠加： 1、行业催化空窗期：缺乏大BD（商务拓展）催化 ...

来源：新浪基金∞工作室 9月18日，港股创新药ETF（159567）收盘涨0.21%，成交额25.65亿元。 港股创新药ETF（159567）成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数 证券投资基金，基金简称为港股创新药ETF。该基金管理费率每年0.50%，托管费率每年0.10%。港股创 新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)。 规模方面，截止9月17日，港股创新药ETF（159567）最新份额为81.71亿份，最新规模为77.68亿元。回 顾2024年12月31日，港股创新药ETF（159567）份额为3.95亿份，规模为3.78亿元。即该基金今年以来 份额增加1966.63%，规模增加1956.03%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 流动性方面，截止9月18日，港股创新药ETF（159567）近20个交易日累计成交金额377.58亿元，日均 成交金额18.88亿元；今年以来， ...

Core Viewpoint - The Trump administration is drafting an executive order that will impose three major restrictions on commercial transactions involving Chinese innovative drug patents or rights, focusing on national security reviews by the Committee on Foreign Investment in the United States (CFIUS) [1][2]. Summary by Sections Executive Order Details - The draft includes three main provisions: 1. Inclusion of Chinese innovative drug BD transactions in the CFIUS mandatory review list, ending the previous "low-risk automatic exemption" practice [2]. 2. FDA will implement "racial sensitivity supplementary reviews" for drugs relying on Chinese clinical data, requiring at least 20% comparative data from non-Asian populations [2]. 3. Establishment of a "key drug domestic production fund" to provide production subsidies for 15 categories of drugs, including antibiotics and acetaminophen, while implementing a "domestic priority" principle in federal procurement [2]. Market Reaction - The market reacted swiftly to the policy risks, with the Hong Kong innovative drug index (HK1105) dropping 3.82% on September 11, 2025, and the A-share innovative drug sector (BK1106) declining 2.17%, with over 80% of stocks in the sector experiencing pullbacks [3]. - The following day, the indices showed signs of recovery, indicating investors' responses to policy uncertainties and rational corrections [3]. Globalization Trends - Despite the geopolitical risks, the trend of Chinese innovative drugs going global remains intact, with total license-out transactions to Europe and the U.S. reaching $9.43 billion as of September 2025 [3]. - Major transactions include a $950 million licensing deal between BeiGene and Royalty Pharma, and a $6 billion global licensing agreement between 3SBio and Pfizer, highlighting a shift towards milestone payments and regional licensing [3]. Industry Challenges - The domestic market faces challenges, with annual growth in medical insurance fund spending (approximately 12%) lagging behind the growth in innovative drug R&D investment (approximately 25%) [4]. - The average reduction in medical negotiations remains high at 54%, and commercial health insurance coverage for innovative drugs is below 15%, creating a supply-demand imbalance that necessitates going global [4]. Risk Resilience Assessment - Goldman Sachs has categorized Chinese innovative drug companies into three risk resilience tiers based on their sensitivity to policy changes and operational capabilities [4][5]. - Companies with mature global layouts exhibit the strongest resilience, while those heavily reliant on domestic markets show the weakest resilience [5][10]. Strategic Defense Framework - A three-dimensional defense system is proposed to address risks associated with the executive order, focusing on transaction review, data compliance, and supply chain security [13]. - Strategies include conducting national security risk pre-assessments for transactions over $50 million and establishing partnerships with U.S. law firms to navigate regulatory challenges [14][15]. Conclusion - The construction of a quantifiable "risk resilience index" is essential for Chinese innovative drugs in the global 2.0 era, emphasizing the need for companies to embed policy hedging clauses in transaction structures and consider racial diversity data in clinical stages [23].

Key Points - The top three stocks with net inflow of southbound funds are Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [1] - The top three stocks with net outflow of southbound funds are Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [1] - In terms of net inflow ratio, Yuexiu Transportation Infrastructure (01052) leads with 63.76%, followed by Crystal International (02232) with 56.34%, and China Resources Gas (01193) with 53.63% [1] - The stocks with the highest net outflow ratio include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [1] Net Inflow Rankings - The top ten stocks by net inflow include Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [2] - Other notable stocks in the net inflow list are Meituan-W (03690) with 0.670 billion and Southern Hang Seng Technology (03033) with 0.620 billion [2] Net Outflow Rankings - The top ten stocks by net outflow include Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [2] - Other significant stocks in the net outflow list are Li Auto-W (02015) with -0.298 billion and China Construction Bank (00939) with -0.254 billion [2] Net Inflow Ratio Rankings - The top three stocks by net inflow ratio are Yuexiu Transportation Infrastructure (01052) at 63.76%, Crystal International (02232) at 56.34%, and China Resources Gas (01193) at 53.63% [3] - Additional stocks with high net inflow ratios include China Ship Leasing (03877) at 49.13% and Jiangsu Ninghu Expressway at 45.49% [3] Net Outflow Ratio Rankings - The stocks with the highest net outflow ratios include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [3] - Other notable stocks with significant net outflow ratios are Kangji Medical (09997) at -53.77% and QiuTai Technology (01478) at -47.17% [3]

【导读】美股震荡收跌，市场静候美联储利率决议；中国资产大涨，纳斯达克中国金龙指数 创新高 中国基金报记者 储是 美股震荡收跌，市场静候美联储利率决议。国际油价和黄金价格走高。 9月16日（周二），美股科技巨头涨跌不一，微软、英伟达和谷歌等加码英国投资，背景是美 国总统特朗普正在英国进行国事访问。 中国资产大涨，纳斯达克中国金龙指数创新高。 美股在震荡交易中收跌 纳斯达克中国金龙指数上涨1.76%，报收于约8600点，创下2022年2月以来的新高。 蔚来、百度集团、京东集团、爱奇艺和阿里巴巴分别上涨8.17%、7.81%、3.24%、 3.11%、2.65%。 9月16日（周二），美股在震荡交易中收跌。 截至收盘，道琼斯工业指数下跌0.27%，报收于45757.90点；纳斯达克指数下跌0.07%，报 收于22333.96点；标普500指数下跌0.13%，报收于6606.76点。 | 美股指数 它 | | | | --- | --- | --- | | 道琼斯 | 纳斯达克 | 标普500 | | 45757.90 | 22333.96 | 6606.76 | | -125.55 -0.27% | -14.79 ...

【导读】美股震荡，中概股大涨 大家好，今晚继续关注海外市场的表现！ 9月16日晚间，美股三大指数震荡下跌，道指微跌160点，纳指接近平盘，标普500指数微跌。交易员在等待美联储决议之际按兵不动，暂不进 行大的押注。 一份稳健的零售销售数据对市场推动有限，美股在历史高位附近摇摆。 美国商务部公布的数据显示，8月份未经通胀调整的零售购买额环比增长0.6%。这一增幅超过了经济学家的所有预期。不包括汽车，销售额增 长了0.7%。 摩根士丹利财富管理的艾伦·曾特纳（Ellen Zentner）表示："美国消费者看起来心情不错。这对经济是利好，但也可能加剧有关美联储需要多 积极降息的争论。" 美元走弱，欧元创下自2021年以来最强水平。黄金一度突破3700美元。 三元指数 < ▼ ▶ 汇 DINIW 96.7549 -0.6021 -0.6184% 09-17 00:00:50 振幅 今开 97.3461 最高 97.3891 0.6869% 昨收 最低 波幅 0.6687 97.3570 96.7204 五日 月K 分时 目K 團K 更多, ◎ 最新:96.7549 -0.6021 -0.6184% 分时成交 97.9 ...

Key Recommendations - The report highlights a significant improvement in short-term loans for enterprises, with a notable increase in demand for short-term financing driven by a slight recovery in manufacturing and the implementation of interest subsidy policies for service industry loans [6][7][9] - The overall economic data for August indicates a continued slowdown, necessitating further policy support to stimulate growth, particularly in investment and consumption sectors [12][13][14] - The pharmaceutical and biotechnology sectors are under scrutiny due to potential U.S. restrictions on drug development collaborations with China, which could reshape the global supply chain dynamics [17][19][20] - The non-bank financial sector shows a steady increase in public fund holdings, with China Pacific Insurance planning to issue convertible bonds to enhance its capital strength [21][24] - The electronics industry is experiencing a mild recovery, with Apple launching the iPhone 17 series, which is expected to drive new replacement demand [26][28][29] Group 1: Banking Sector Insights - The People's Bank of China reported that the social financing scale increased by 8.8% year-on-year, while the growth rate of RMB loans was 6.6%, indicating a stable lending environment [6][7] - The government continues to push for increased financing through government bonds, with a notable increase in government debt issuance in August, which supports the overall social financing growth [8][9] - The report suggests that future credit growth will focus more on optimizing the structure rather than just increasing total volume, with an emphasis on supporting small and medium enterprises and innovation-driven sectors [9][11] Group 2: Economic Data Analysis - August retail sales growth slowed to 3.4% year-on-year, reflecting a decline in consumer demand, particularly in the goods retail sector [12][13] - Fixed asset investment showed a cumulative year-on-year growth of only 0.5%, indicating a significant drag on economic performance from the investment side [12][14] - The real estate sector continues to face challenges, with new home sales dropping by 10.6% year-on-year, highlighting the ongoing pressures in the housing market [16] Group 3: Pharmaceutical and Biotechnology Sector - The pharmaceutical sector's performance was negatively impacted by geopolitical tensions, with a decline in stock prices for Chinese biotech firms listed in the U.S. following news of potential U.S. restrictions [19][20] - Despite the challenges, the report emphasizes the resilience of the innovative drug sector, suggesting continued investment in high-performing stocks within this space [20] Group 4: Non-Bank Financial Sector - The public fund management sector has seen a steady increase in assets, with significant growth in equity and non-monetary funds [21][23] - China Pacific Insurance's issuance of convertible bonds is expected to enhance its competitive position and support its strategic initiatives [24] Group 5: Electronics Industry Developments - The launch of the iPhone 17 series is anticipated to stimulate demand in the electronics sector, particularly for high-end devices [26][28] - The report notes that the electronics industry is gradually recovering, with a focus on domestic production and supply chain resilience in response to international pressures [27][30]